Literature DB >> 18936690

Prostate cancer with tertiary Gleason pattern 5 in prostate needle biopsy: clinicopathologic findings and disease progression.

Kiril Trpkov1, Jianguo Zhang, Melissa Chan, Bernhard J C Eigl, Asli Yilmaz.   

Abstract

Significance of tertiary Gleason pattern/grade 5 on prostatectomy has been studied, but its significance on biopsy remains uncertain. Recent International Society of Urological Pathology consensus conference recommended that biopsy Gleason score is generated by adding tertiary grade 5 to the primary grade. We examined the preoperative clinical and biopsy findings in 53 patients with biopsy tertiary pattern 5 and 119 patients with primary/secondary biopsy pattern 5. Prostatectomy findings and prostate-specific antigen (PSA) failure rates were compared in surgically treated patients. Cause-specific and all-cause mortality were compared in patients treated nonsurgically. At presentation, age, gland volume, PSA, and biopsy cancer volume were similar in patients with tertiary and primary/secondary grade 5. Only 20 patients underwent prostatectomy and 152 were treated nonsurgically. Regardless of the pattern, patients treated by prostatectomy were younger (P=0.003), had lower PSA (P=0.001), and less cancer on biopsy (P=0.0001). Prostatectomy findings and PSA failures were not significantly different in patients with tertiary grade 5 versus primary/secondary pattern 5. In nonsurgically treated patients, patients with primary pattern 5 compared with those with tertiary pattern 5 had a significantly higher risk of all-cause mortality [adjusted hazard ratio (HR): 2.33, 95% confidence interval (CI): 1.10-4.90, P=0.026] and cause-specific mortality (adjusted HR: 7.52, 95% CI: 2.84-19.87, P<0.001). In contrast, patients with secondary pattern 5 had a comparable all-cause mortality risk to patients with tertiary pattern 5 (adjusted HR: 1.04, 95% CI: 0.47-2.32, P=0.92), but had a marginally higher risk of cause-specific mortality than patients with tertiary pattern 5 (adjusted HR: 2.13, 95% CI: 0.75-6.10, P=0.16).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18936690     DOI: 10.1097/PAS.0b013e31817fb3bd

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  2 in total

1.  ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading.

Authors:  Paul Mak; Irwin Leav; Bryan Pursell; Donggoo Bae; Xiaofang Yang; Cherie A Taglienti; Lindsey M Gouvin; Vishva M Sharma; Arthur M Mercurio
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

2.  Clinical outcome comparison of Grade Group 1 and Grade Group 2 prostate cancer with and without cribriform architecture at the time of radical prostatectomy.

Authors:  Eva Hollemans; Esther I Verhoef; Chris H Bangma; John Rietbergen; Monique J Roobol; Jozien Helleman; Geert J L H van Leenders
Journal:  Histopathology       Date:  2020-04       Impact factor: 5.087

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.